An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)

This study is a randomized, placebo-controlled, double-blind, multicenter Phase 2/3 study of patients, age 12 to 65 years (inclusive), with sickle cell disease (SCD) and the primary objectives are: 1) To assess the effectiveness of study drug in adolescent and adults with SCD as compared to placebo as measured by improvement in hemoglobin (Hb) 2) To characterize the effectiveness of study drug as compared to placebo on the annual rate of pain crises